Skip to main content
Today's Change
Volume
Real-Time Last Update TSX Last Sale

More stories below advertisement

Latest Press Releases

Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme
- GlobeNewswire - Wed Dec 2, 6:00AM CST
GlobeNewswire - CMTX
Wed Dec 2, 6:00AM CST
- Call will take place on Friday, December 11, 2020 at 11:00 AM ET
Medicenna to Participate in Upcoming December Investor Conferences
- GlobeNewswire - Mon Nov 23, 6:51AM CST
GlobeNewswire - CMTX
Mon Nov 23, 6:51AM CST
Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will be participating in fireside chats and virtual 1x1 investor meetings at the Piper Sandler 32 Annual Virtual Healthcare Conference and the Evercore ISI 3 Annual HealthCONx Conference. See below for more details.
Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual Meeting
- GlobeNewswire - Wed Nov 18, 6:02AM CST
GlobeNewswire - CMTX
Wed Nov 18, 6:02AM CST
Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two on-demand oral presentations as part of the 2020 Society for Neuro-Oncology (SNO) Annual Meeting, which is being held virtually from November 19-21, 2020.
Medicenna Reports Second Quarter Fiscal 2021 Financial Results and Operational Highlights
- GlobeNewswire - Fri Nov 13, 6:00AM CST
GlobeNewswire - CMTX
Fri Nov 13, 6:00AM CST
Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.
Medicenna to Present at Upcoming Scientific and Investor Events in November
- GlobeNewswire - Mon Nov 2, 6:30AM CST
GlobeNewswire - CMTX
Mon Nov 2, 6:30AM CST
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will present at the Next-Gen Cytokine Therapeutics Summit, Stifel 2020 Virtual Healthcare Conference, as well as participate in the SVB Leerink Oncology 1x1 Day. All events are being held in November 2020. See below for more details.
Medidata Synthetic Control Arm(R) Supported by the US Food and Drug Administration (FDA) for Use in Medicenna Therapeutics, Corp. Phase 3 Registrational Trial in Recurrent Glioblastoma
- BusinessWire - Wed Oct 28, 5:00AM CDT
BusinessWire - CMTX
Wed Oct 28, 5:00AM CDT
Medidata, a Dassault Systemes Company, today announced that the US Food and Drug Administration (FDA) supported the use of a Medidata Synthetic Control Arm(R) in a phase 3 registrational trial in recurrent glioblastoma (rGBM). This is a precedent setting acceptance of a hybrid external control (combining synthetic control arm patients with randomized patients) in a phase 3 trial in an indication that previously used traditional randomized controls.
Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual Meeting
- GlobeNewswire - Mon Oct 19, 6:00AM CDT
GlobeNewswire - CMTX
Mon Oct 19, 6:00AM CDT
Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two abstracts at the EORTC-NCI-AACR ("ENA") Virtual Scientific Program on Molecular Targets and Cancer Therapeutics to be held from October 24 - 25, 2020.
Dr. Jack Geltosky Elected to Medicenna Board of Directors
- GlobeNewswire - Wed Sep 30, 3:30PM CDT
GlobeNewswire - CMTX
Wed Sep 30, 3:30PM CDT
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Dr. John (Jack) Geltosky to the Board of Directors of Medicenna and the voting results from the Company's annual and special meeting of shareholders held today, September 30, 2020 in Toronto (the "Meeting"). A total of 61.56% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
Medicenna to Present at Upcoming Investor Conferences in September
- GlobeNewswire - Wed Sep 9, 6:00AM CDT
GlobeNewswire - CMTX
Wed Sep 9, 6:00AM CDT
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will present at the virtual H.C. Wainwright 22 Annual Global Investment Conference 2020, as well as participate in a fireside chat at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Both conferences are being held in September 2020. See below for more details.
Medicenna to Commence Trading on Nasdaq
- GlobeNewswire - Thu Aug 20, 3:40PM CDT
GlobeNewswire - CMTX
Thu Aug 20, 3:40PM CDT
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that the Company's common shares have been approved for listing on The Nasdaq Capital Market ("Nasdaq"). Trading is expected to begin on Monday, August 24, 2020, under the symbol "MDNA" on the Nasdaq. The Corporation will retain its listing on the Toronto Stock Exchange under the symbol "MDNA" and the Company's common shares will continue to trade on the OTCQB under the symbol "MDNAF" until trading on the Nasdaq commences.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies